BioVaxys Technology Corp. Reports Successful Close of Unsecured Convertible Debenture Offering

Vancouver, BC – 16 September 2025 – BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB) announced the successful closure of a private placement of unsecured convertible debentures, raising a total of CAD 335,670 in aggregate gross proceeds. The offering, completed in a non‑brokered manner, reflects continued confidence from investors in the company’s pipeline and strategic focus on vaccine and immunotherapy development.

Key Terms of the Debentures

  • Maturity: 30 August 2026
  • Interest: 10 % per annum, payable quarterly in cash or, at the company’s discretion, in common shares (“Shares”) of BioVaxys.
  • Conversion: At the holder’s option, the principal can be converted into Shares at any time, using the closing price of the Shares on the Canadian Securities Exchange (CSE) on the day the conversion notice is received. Accrued interest up to the conversion date will also be satisfied in shares.
  • Conversion Ratio: For every CAD 1,000 of debentures, holders receive 4,000 shares, providing an attractive incentive for conversion and aligning investor interests with the company’s equity performance.

Strategic Implications

The infusion of capital underscores BioVaxys’s robust financial footing and enables continued investment in its flagship product, VaxMite, a novel vaccine aimed at protecting against Plasmodium falciparum, the most lethal form of malaria. The company’s broader portfolio—encompassing potential applications in infectious diseases and oncology—benefits from the additional resources required to scale pre‑clinical and early clinical programs.

By opting for a convertible structure, BioVaxys has secured short‑term liquidity while preserving long‑term upside for investors. The 10 % interest rate is competitive within the biotechnology sector, reflecting the company’s moderate risk profile and the strategic value of its technology platform.

Market Reception

The closing of the offering was reported by multiple financial outlets, including StockWatch, The CSE, and Finanznachrichten.de. Despite a current trading price of CAD 0.24 and a 52‑week range of CAD 0.20–0.80, the successful raise demonstrates investor appetite for BioVaxys’s growth prospects.

Forward‑Looking Outlook

With the capital in place, BioVaxys is poised to advance VaxMite through pivotal pre‑clinical milestones, potentially positioning the company for an upcoming clinical trial launch. Simultaneously, the convertible mechanism ensures that equity dilution remains contingent on the company’s valuation trajectory, thereby safeguarding shareholder value.

BioVaxys’s leadership remains committed to delivering breakthrough solutions for global health challenges, and the recent debenture offering represents a strategic step toward realizing that mission.